Home > Journals > Minerva Pediatrica > Past Issues > Articles online first > Minerva Pediatrica 2019 Dec 11

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Pediatrica 2019 Dec 11

DOI: 10.23736/S0026-4946.19.05567-1

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Combination of prednisolone and cyclosporin A as third-line therapy for refractory Kawasaki disease: a case study

Masamune HIGASHIGAWA , Tomomi NAKAMURA, Tomoki HATTORI, Ayako YOSHINO, Mitsue ITO, Ryoji ICHIMI

Department of Pediatrics and Neonatology, Japanese Red Cross Ise Hospital, Ise, Japan


PDF


BACKGROUND: The selection of drugs as third-line therapy for patients with Kawasaki disease (KD) who are resistant to second-line therapy remains controversial.
METHODS: We reviewed the medical records of 354 patients (216 males/137 females) with KD who were treated in our department from July 2003 to January 2016. The age range was 1 month to 10 years, and the median age was 2 years and 1 month. A combination of 2 g/kg intravenous immunoglobulin (IVIG) plus 30 mg/kg of aspirin was used as first-line therapy. Patients who were refractory to the first-line therapy were administered 2 mg/kg of prednisolone (PSL) in combination with IVIG. Five patients who were refractory to the second-line therapy were treated with cyclosporine A (CsA) combined with PSL as the thirdline therapy.
RESULTS: All five patients immediately responded to the third-line therapy. One of the five patients showed a transient dilatation of the coronary artery that regressed to its normal size by the 60th day of illness.
CONCLUSIONS: We suggest that the combination of CsA and steroids might be a promising therapeutic strategy for refractory KD.


KEY WORDS: Kawasaki disease; Cyclosporine A (CsA); Steroids; Intravenous immunoglobulin (IVIG)

top of page